Article and Video CATEGORIES

Cancer Journey

Search By

Patient Education Ambassador Program - Rafeh Naqash MD, Understanding Clinical Trials Part 2
dbrock
2020 PEA Program - Rafeh Naqash MD, Clinical Trials Series with Ivy Elkins and Dr. Fumiko Chino MD
Author
Abdul Rafeh Naqash, MD
Image
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials.

 

For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino).

In these videos, Drs. Naqash and Chino and Ms. Elkins discuss:
  1. Are Placebos Used in Phase 1 Clinical Trials?  How Does this Differ from Trials in Other Phases?
  2. Could A Trial Be Right For Me Even If My Doctor Didn't Know About It?
  3. How Do I Manage Potential Side Effects I Might Experience on a Clinical Trial?
  4. How Will Being on a Trial Potentially Impact My Daily Life?
  5. How Much Will a Clinical Trial Cost?  How Does the Billing Work, and What About Emergency Treatment and Other Expenses?  
  6. Does A Clinical Trial Have Provisions or Resources for Stress or Mental Health?
  7. What Happens if I Have To Leave a Clinical Trial?

 

 

#clinicaltrial #genentech #lilly #cancerGRACE

 

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on